UroToday.com

@urotoday

Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology

Reno, NV

Joined February 2009

UroToday.com
@urotoday
17h
OPTION-DDR and personalized platinum chemotherapy in HRR-mutated #mCRPC. Michael Ong, MD, FRCPC @OttawaHospital joins @zklaassen_md to discuss OPTION-DDR, a phase 3 randomized trial of 236 patients comparing docetaxel plus carboplatin against docetaxel alone in HRR-mutated
UroToday.com
@urotoday
18h
ECOG-ACRIN 8192 evaluates preoperative gemcitabine + durvalumab in cisplatin-ineligible #UTUC. @JCensits @hopkinskimmel joins @TiansterZhang @UTSWMedCenter to discuss a prospective study of four cycles of preoperative gemcitabine plus durvalumab before radical nephroureterectomy
UroToday.com
@urotoday
19h
Indi-Blade Study tests ipilimumab-nivolumab followed by chemoradiotherapy in advanced #BladderCancer. @MichvdHeijden @NKI_nl & Jan-Jaap Mellema, MD join @l_ballas @CedarsSinai in this discussion on UroToday. Key findings from ipilimumab + nivolumab followed by consolidative
UroToday.com
@urotoday
20h
Single-arm trials and hazard ratio interpretation in #NMIBC. Cathy Yuan, MD, MSc, PhD @UHN joins @UroDocAsh @UTMDAnderson to discuss the methodological basis for single-arm trials in BCG-unresponsive NMIBC and hazard ratio interpretation. Single-arm designs are justified when BCG
UroToday.com
@urotoday
21h
Perioperative immunotherapy vs risk-adapted adjuvant therapy in #MIBC. @giannatempopatr @IstTumori & @tompowles1 @QMBCI join @UroDocAsh @UTMDAnderson to discuss perioperative immunotherapy in muscle-invasive bladder cancer. Key takeaways: 🔹 Dr. Powles: EV + pembro + cystectomy